Status:
COMPLETED
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
Brief Summary
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have been administered with Nexavar for unresectable or advanced ...
Eligibility Criteria
Inclusion
- Patients who received Nexavar for unresectable or advanced renal cell carcinoma
Exclusion
- Patients who are contraindicated based on the product label
Key Trial Info
Start Date :
April 18 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2016
Estimated Enrollment :
3305 Patients enrolled
Trial Details
Trial ID
NCT01411423
Start Date
April 18 2008
End Date
February 28 2016
Last Update
June 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan